Clinical Trial Update: Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating pembrolizumab for recurrent high-grade neuroendocrine carcinoma (neuroendocrine tumors) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Neuroendocrine Tumors

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Utah | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2020-01-27